Analysis

Heron Therapeutics, Inc. (HRTX) Stock Analysis

Heron Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to HRTX.

websiteHRTX/analysis/HRTX

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to HRTX.

Stock profile

Ticker

HRTX

Asset type

Stock

Market cap

$79.0M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Heron Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • HRTX primary listing
  • A1XB6K
  • 0J4V
  • AXD2

Latest Heron Therapeutics, Inc. news

U.S. District Court Issues Decision Regarding CINVANTI® Patents

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settle...

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that...

Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year

Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that ...

Research sections

Valuation

Review valuation context for Heron Therapeutics, Inc..

Future growth

Review future growth context for Heron Therapeutics, Inc..

Past performance

Review past performance context for Heron Therapeutics, Inc..

Financial health

Review financial health context for Heron Therapeutics, Inc..

Dividend

Review dividend context for Heron Therapeutics, Inc..

Management

Review management context for Heron Therapeutics, Inc..

Ownership

Review ownership context for Heron Therapeutics, Inc..

Other information

Review other information context for Heron Therapeutics, Inc..

Community

Review community context for Heron Therapeutics, Inc..